Clinical Trial Results Cagrilintide offers comparable weight loss to GLP-1 therapies with a potentially better tolerability profile for some patients
Reduced L-Glutathione, Fructose (bulking agent), Sorbitol (bulking agent), Microcrystalline cellulose (bulking agent), Sodium croscarmellose (bulking agent), Citric acid (bulking agent), Stearic acid (anti-caking agent), Natural cherry flavour (bulking agent), Silica (anti-caking agent), Magnesium stearate (anti-caking agent)
These results imply that the pathophysiology of microvascular complications in type 2 diabetes may be influenced by vitamin D deficiency
Its potential to enhance recovery and preserve lean tissue makes it appealing for both athletes and those recovering from physical stress
Both are once-weekly subcutaneous injections titrated upward over weeks to a maintenance dose, a schedule designed to blunt gastrointestinal side effects